The European Commission has authorized ViiV Healthcare's Apretude (cabotegravir long-acting injectable and tablets) for HIV prevention, GSK plc (GSK,GSK.L) said in a statement on Tuesday.Cabotegravir is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents (at least 12 years of age), weighing at least 35 kg.Cabotegravir long-acting injectable and tablets for PrEP is the first and only HIV prevention option approved in the European Union that reduces the number of doses needed for effective HIV prevention from 365 daily pills to as few as six injections per year.According to the company, Cabotegravir long-acting injectable and tablets for PrEP has demonstrated superior efficacy to daily oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in reducing the risk of HIV acquisition in clinical trials..

欧盟委员会已授权ViiV Healthcare的预防艾滋病毒的药物（cabotegravir长效注射剂和片剂），GSK plc（GSK，GSK.L）在星期二的一份声明中表示。Cabotegravir与更安全的性行为相结合，用于暴露前预防（PrEP），以降低高危成人性获得性HIV-1感染的风险和青少年（至少12岁），体重至少35公斤.Cabotegravir长效注射剂和PrEP片剂是欧盟批准的第一个也是唯一一个将有效预防艾滋病毒所需剂量从365粒每日药丸减少到少至6粒注射剂每年。据该公司称，Cabotegravir长效注射剂和PrEP片剂在降低临床试验中HIV感染风险方面表现出优于每日口服恩曲他滨/替诺福韦二吡呋酯富马酸盐（FTC/TDF）的疗效。。

Cabotegravir long-acting for PrEP is approved for use in the US, Australia, South Africa, as well as other countries as Apretude. Submission to other regulatory agencies is on-going.ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK and Pfizer (PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention options.For More Such Health News, visit rttnews.com For comments and feedback contact: editorial@rttnews.comBusiness News.

Cabotegravir长效PrEP被批准在美国，澳大利亚，南非以及其他国家使用。正在向其他监管机构提交申请.ViiV Healthcare是由葛兰素史克和辉瑞（PFE）于2009年11月成立的全球专科艾滋病毒公司，致力于为艾滋病毒感染者和可从中受益的人提供治疗和护理方面的进展。艾滋病预防方案。有关更多此类健康新闻，请访问rttnews.com获取评论和反馈联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票